Details of the Drug Combination

General Information of Drug Combination (ID: DC1RSOU)

Drug Combination Name
Bendamustine hydrochloride ER819762
Indication
Disease Entry Status REF
Astrocytoma Investigative [1]
Component Drugs Bendamustine hydrochloride   DMFH15Z ER819762   DMSG91J
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: U251
Zero Interaction Potency (ZIP) Score: 5.53
Bliss Independence Score: 7.93
Loewe Additivity Score: 5.59
LHighest Single Agent (HSA) Score: 6.05

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Bendamustine hydrochloride
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Approved [2]
Bendamustine hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [2]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [5]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [4]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [4]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [6]
PRKC apoptosis WT1 regulator protein (PAWR) OTKY7W52 PAWR_HUMAN Decreases Expression [4]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Increases Localization [4]
Death domain-associated protein 6 (DAXX) OTX6O7PL DAXX_HUMAN Decreases Expression [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)
Indication(s) of ER819762
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
ER819762 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Antagonist [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCN133M MOLT-4 Investigative [1]
Astrocytoma DC4R46M SNB-19 Investigative [1]
Chronic myelogenous leukemia DCUH8YL K-562 Investigative [1]
Renal cell carcinoma DCOUJG7 SN12C Investigative [1]
Renal cell carcinoma DCEHLPP UO-31 Investigative [1]
Colon adenocarcinoma DCD4Z31 COLO 205 Investigative [8]
Invasive ductal carcinoma DCVJ3CY T-47D Investigative [8]
Adenocarcinoma DCZDC18 DU-145 Investigative [9]
Adenocarcinoma DCYTVNO OVCAR3 Investigative [9]
Adenocarcinoma DCOIPV3 A549 Investigative [9]
Adenocarcinoma DC4X1OX HCT-15 Investigative [9]
Adenocarcinoma DC9C10M SW-620 Investigative [9]
Adenocarcinoma DCP3B3J HCT116 Investigative [9]
Cutaneous melanoma DCIZ3VS SK-MEL-5 Investigative [9]
High grade ovarian serous adenocarcinoma DCT7AA4 OVCAR-5 Investigative [9]
Large cell lung carcinoma DCTRK6S NCI-H460 Investigative [9]
Lung adenocarcinoma DCKDSZ9 HOP-62 Investigative [9]
Lung adenocarcinoma DCE2HNU NCI-H522 Investigative [9]
Malignant melanoma DCGEBSR UACC62 Investigative [9]
Melanoma DC5IV2K SK-MEL-2 Investigative [9]
Mixed endometrioid and clear cell carcinoma DCFYZAL IGROV1 Investigative [9]
Prostate carcinoma DCWI0RX PC-3 Investigative [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4040).
4 Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
5 Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54.
6 Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma. 2004 Jul;45(7):1429-36. doi: 10.1080/1042819042000198858.
7 A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310.
8 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
9 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976